Polymorphic variability in the 3' untranslated region (UTR) of IL12B is associated with susceptibility to severe anaemia in Kenyan children with acute Plasmodium falciparum malaria by Ong'echa, John M et al.
RESEARCH ARTICLE Open Access
Polymorphic variability in the 3’ untranslated
region (UTR) of IL12B is associated with
susceptibility to severe anaemia in Kenyan children
with acute Plasmodium falciparum malaria
John M Ong’echa
1,2, Evans O Raballah
1,3, Prakasha M Kempaiah
2, Samuel B Anyona
1, Tom Were
1,
Gregory C Davenport
2, Stephen Konah
1, John M Vulule
4, Collins Ouma
1, James B Hittner
5 and
Douglas J Perkins
1,2*
Abstract
Background: Plasmodium falciparum malaria remains a leading cause of morbidity and mortality among African
children. Innate immunity provides the first line of defence against P. falciparum infections, particularly in young
children that lack naturally-acquired malarial immunity, such as the population examined here. Consistent with the
fact that elevated interleukin (IL)-12 is an important component of the innate immune response that provides
protective immunity against malaria, we have previously shown that suppression of IL-12 in African children is
associated with the development of severe malarial anaemia (SMA). Since the role of IL12B variants in conditioning
susceptibility to SMA remains largely unexplored, the association between a single nucleotide polymorphism
(1188A®C, rs3212227), SMA (Hb<6.0g/dL), circulating IL-12p40/p70 levels, and longitudinal clinical outcomes in
Kenyan children (n = 756) residing in a holoendemic falciparum malaria transmission area were investigated.
Results: Multivariate logistic regression analysis in children with acute malaria (n = 544) demonstrated that carriers
of the C allele had increased susceptibility to SMA (CC: OR, 1.674; 95% CI, 1.006-2.673; P = 0.047, and AC: OR, 1.410;
95% CI, 0.953-2.087; P = 0.086) relative to wild type (AA). Although children with SMA had lower IL-12p40/p70
levels than the non-SMA group (P = 0.037), levels did not differ significantly according to genotype. Longitudinal
analyses in the entire cohort (n = 756) failed to show any significant relationships between rs3212227 genotypes
and either susceptibility to SMA or all-cause mortality throughout the three year follow-up.
Conclusion: The rs3212227 is a marker of susceptibility to SMA in children with acute disease, but does not appear
to mediate functional changes in IL-12 production or longitudinal outcomes during the acquisition of naturally-
acquired malarial immunity.
Background
Plasmodium falciparum accounts for approximately 98%
of the reported malaria cases in Africa and is a leading
cause of morbidity and mortality among African chil-
dren [1]. In areas with holoendemic P. falciparum trans-
mission, such as western Kenya, severe malaria primarily
manifests as severe malarial anaemia [SMA,
haemoglobin, (Hb<6.0 g/dL)] with a peak incidence
between 7-24 mos. of age [2]. Although SMA in western
Kenya can occur in the presence or absence of high-
density parasitaemia (HDP, ≥10,000 parasites/μL), the
overall level of concomitant peripheral parasitaemia
appears less important in determining anaemia severity
than the presence of chronic or repeated infections that
precipitously reduce Hb concentrations over time [3,4].
Interleukin (IL)-12 is a pro-inflammatory cytokine
released by monocytes/macrophages, B cells, and den-
dritic cells as part of the host immune response to
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demonstrated that subcutaneous injection of recombi-
nant IL-12 prior to challenge with P. cynomolgi comple-
tely protected against infection, possibly through an
interferon (IFN)-g-dependent mechanism [7]. Our pre-
vious studies in Gabonese and Kenyan children with
malaria showed that suppression of circulating IL-12
was associated with decreased Hb concentrations [8,9].
These results are consistent with studies in murine
models showing that IL-12 protects against malaria by
enhancing erythropoiesis and, thereby, reducing severe
anaemia [10]. Thus, unlike a number of other cytokines
that show divergent results in differing species, the asso-
ciation between reduced IL-12 production and enhanced
malaria disease severity appears conserved across the
phylogenetic spectrum.
IL-12 is a heterodimer composed of IL-12p35 and IL-
12p40 subunits, encoded by IL12A and IL12B genes
located on chromosomes 3p12-q13.2 and 5q31-33,
respectively [11]. A number of single nucleotide poly-
morphisms (SNPs) have been identified in the IL12B
gene, including an IL12B promoter polymorphism
(IL12Bpro, rs17860508) and a TaqI polymorphism (an A
to C transition at 1188, rs3212227) in the IL12B 3’
untranslated region [12,13]. Previous case-control stu-
dies revealed that the IL12Bpro polymorphism was asso-
ciated with enhanced mortality and reduced peripheral
nitric oxide (NO) production in Tanzanian children
with cerebral malaria, whereas variation at this position
had no relationship with disease outcomes in Kenyan
children with severe malaria [14]. Investigation of IL12B
polymorphisms in a family-based association study
showed that IL12Bpro was associated with an increased
risk of cerebral malaria in Malian children, while
rs3212227 polymorphic variability had no significant
relationship with susceptibility to cerebral malaria [15].
However, the rs3212227 polymorphism has been asso-
ciated with susceptibility to the development of autoim-
mune diseases [16], type 1 diabetes mellitus [17],
multiple sclerosis [18,19] lepromatous leprosy [20] and
Chagas’ disease [21]. In vitro investigations also suggest
that differing rs3212227 genotypes functionally influence
IL-12 production [13,22].
More recently, our studies among an adult Thai popu-
lation showed that carriage of the rs3212227 CC geno-
type was associated with severe malaria [23]. A recent
community-based longitudinal investigation in a paedia-
tric population in western Kenya, however, observed no
association between the rs3212227 variants and SMA,
but several significant relationships between SMA and
copy number variation in IL12A and IL12RB1 [24]. To
further explore the role of rs3212227 variants in condi-
tioning susceptibility to SMA, cross-sectional and longi-
tudinal studies were performed in a comprehensively
phenotyped paediatric population (n = 756) in Siaya
District, western Kenya. We observed that among chil-
dren presenting with acute falciparum malaria, carriers
of the C allele had increased susceptibility to SMA com-
pared to those with the wild type allele (AA), although
IL-12p70 levels did not differ according to genotypes. In
addition, longitudinal analyses did not show any signifi-
cant relationships between the rs3212227 genotypes and
either repeated episodes of SMA or all-cause mortality
during the three year follow-up period.
Methods
Study participants
Recruitment took place at Siaya District Hospital (SDH),
a rural government health facility in a holoendemic P.
falciparum transmission area of western Kenya [4]. All
study participants were from the Luo ethnic group.
Further details about the study site and clinical manifes-
tations of paediatric malaria in this geographic region
can be found in our previous report [25]. A total of 756
children were recruited and included children presenting
at the paediatric ward for treatment of febrile illnesses
and those visiting the Mother and Child Health Clinic
for childhood vaccinations. Enrolment was confined to
those children presenting for their first documented
‘hospital contact’. Children who had previously been
hospitalized or had reported antimalarial use within two
weeks prior to presentation at hospital were excluded
from the study. None of the participants in the study
had cerebral malaria or non-P. falciparum species of
malaria.
For the cross-sectional analyses, children with P. falci-
parum malaria upon enrolment (Day 0, n = 544, 3-36
mos.), were stratified into two groups: non-SMA [Hb≥6.0
g/dL and P. falciparum-smear positive (density>1.0), n =
304 and SMA [Hb<6.0 g/dL and P. falciparum-smear
positive (density>1.0), n = 240]. SMA was defined as
Hb<6.0 g/dL (with any density parasitaemia) based on a
previous longitudinal study examining the distribution of
>14,000 Hb measurements in an age- and geographically-
matched population in western Kenya [4]. This definition
of SMA is appropriately defined by Hb distributions
according to age, gender, and geographical context. Non-
SMA was defined as Hb≥6.0 g/dL (with any density
parasitaemia). In addition, to place the current findings
into a global context, SMA (in the multivariate models)
was also defined according to the World Health Organi-
zation (WHO) definition of SMA: Hb<5.0 g/dL with any
density parasitaemia [26], while non-SMA was defined as
Hb≥5.0 g/dL.
Since our previous investigations in this region
demonstrated that HIV-1 status [27] and bacterial co-
infection [28] enhance the development of anaemia in
children with malaria, all study participants were tested
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Pre- and post-HIV test counselling was provided for the
parents/guardians of all study participants. Children
were treated according to Ministry of Health (MoH),
Kenya guidelines. Informed consent in the language of
choice (i.e., English, Kiswahili, or Dholuo) was obtained
from the parents/guardians of all participants. The study
was approved by the ethical and scientific review com-
mittees at the Kenya Medical Research Institute and the
Institutional Review Board at the University of New
Mexico.
Longitudinal follow-up
Following enrolment, parents/guardians were asked to
bring their child back every 3 mos. throughout the 3 yr.
follow-up period. Since the exact location of each child’s
residence was determined upon enrolment with a GIS
surveillance system, children who did not present for
the quarterly follow-up visit were located by the study
team within two days following the missed visit. In addi-
tion, since children in this region experience multiple
episodes of malaria, and other paediatric infectious dis-
eases, parents/guardians were asked to return to the
hospital during their child’s febrile episode(s). At each
acute and quarterly visit, all laboratory tests required for
proper clinical management of the patients were per-
formed, including complete haematological indices,
malaria parasitaemia measures, and evaluation of bacter-
emia (if clinically indicated). In addition, mortality data
was collected throughout the 3 yr. follow-up. Although
most children die at their residence, visits by our study
team determined mortality data for those children that
did not return for their follow-up visits. Mortality data,
along with clinical and laboratory measures were used
to evaluate the association between the genotypes and
SMA, as well as mortality over a three year follow-up
period.
Clinical laboratory measures
Venous blood samples (<3.0 mL) were collected into
EDTA-containing Vacutainer
® tubes, prior to adminis-
tration of any treatment interventions. Asexual malaria
parasites (trophozoites) were counted against 300 leuko-
cytes in peripheral blood smears stained with 10%
Giemsa. Parasite densities were estimated using the fol-
lowing formula: parasite density/μL = white blood cell
(WBC) count/μL × trophozoites/300. Complete haema-
tological parameters were determined with a Beckman
Coulter
® AcT diff2™ (Beckman-Coulter Corporation).
Sickle-cell trait (HbAS) was determined by Hb electro-
phoresis according to the manufacturer’s instructions
(Helena Laboratories). HIV-1 exposure and HIV-1 infec-
tion were determined by serological and PCR testing,
respectively, according to our published methods [27].
Trimethoprim-sulfamethoxazole was administered to all
children that were positive for one or both serological
HIV-1 tests. At the time of sample collection, none of
the HIV-1(+) study participants had been initiated on
antiretroviral treatment. For bacteremia testing, ~1.0 mL
of whole blood was collected aseptically into sterile pae-
diatric Isolator
® microbial tubes (Wampole™ Labora-
tories) and presence of blood-borne bacterial pathogens
was determined according to our previous methods [28].
rs3212227 SNP genotyping
DNA was extracted from buccal swabs using the Bucca-
lAmp™ DNA extraction kit (Epicentre Biotechnologies).
Genomic DNA was amplified using the Genomiphi
DNA amplification kit (GE Healthcare, Life Sciences,
Amersham), and the rs3212227 was genotyped using a
Taqman
® 5’ allelic discrimination Assay-By-Design
method according to manufacturer’s instructions (Assay
ID: C_2084293_10; Applied Biosystems).
Determination of IL-12 production
Plasma samples were obtained from venous blood and
snap-frozen at -80°C until use. IL-12p40/p70 concentra-
tions were determined using the Cytokine 25-plex Ab
Bead Kit, Hu (BioSource™ International) according to
the manufacturer’s protocol. Plates were read on a
Luminex 100™ system (Luminex Corporation) and ana-
lyzed using the Bio-Plex Manager Software (Bio-Rad
Laboratories). The level of detection for IL-12p40/p70
was >4.0 pg/mL.
Statistical analyses
Statistical analyses were performed using SPSS (Version
15.0). Chi-square (c
2)a n a l y s e sw e r eu s e dt oc o m p a r e
proportions. Circulating levels of IL-12 were log-trans-
formed towards normality prior to analyses. ANOVA
tests were used to examine differences in IL-12 levels
across the three genotypic groups. Differences in IL-12
levels between the non-SMA and SMA groups were
determined using independent groups t-test. Deviations
from Hardy-Weinberg Equilibrium (HWE) were tested
using a web-based tool http://www.tufts.edu/
~mcourt01/Documents/Court%20lab%20-%20HW%
20calculator.xls. Cross-sectional associations between
the rs3212227 genotypes and SMA in parasitaemic chil-
dren were determined by a multivariate logistic regres-
sion model, controlling for the confounding effects of
age, gender, HIV-1 status (this included both HIV-1
exposed and positive children), bacteremia, and sickle-
cell trait (HbAS). In addition, hierarchical logistic
regression was used to investigate the association
between genotype and longitudinal outcomes (i.e., SMA
and mortality). For each analysis, covariates (i.e., age,
gender, sickle cell trait, HIV-1 and bacteremia status)
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entered into block 2. Statistical significance was set at P
≤ 0.050 for all tests.
Results
Demographic, parasitological, and clinical characteristics
of parasitaemic children upon enrolment
To determine the impact of polymorphic variation at
the rs3212227 locus on susceptibility to SMA in chil-
dren with acute infection, children with P. falciparum
infections (upon enrolment) were stratified into two
clinical categories: non-SMA (Hb≥6.0 g/dL, n = 304)
and SMA (Hb<6.0 g/dL, n = 240). The demographic,
clinical, and laboratory characteristics of the parasitae-
mic study participants are summarized in Table 1.
Although gender was comparable in the two groups (P
= 0.268), children presenting at hospital with SMA were
younger (mos., P < 0.001) and had lower axillary tem-
peratures (°C, P < 0.001). Consistent with the ap r i o r i
grouping based on Hb (g/dL) concentrations, Hb levels
differed between the groups (P < 0.001). In addition,
children presenting with SMA had leucocytosis relative
to the non-SMA group (P < 0.001). Peripheral parasite
density (/μL) and the geometric mean parasitaemia were
comparable between groups (P = 0.446 and P = 0.678,
respectively). However, the non-SMA group had an ele-
vated prevalence of high-density parasitaemia (HDP,
≥10,000 parasites/μL, P = 0.057). Similarly, the non-
SMA group had a higher proportion of children with
sickle-cell trait (HbAS) compared to the SMA group
(16.1% vs. 2.5%; P = 0.054).
Distribution of IL12B 3’ UTR genotypes in children with
malaria
Genotypes were generated using a Taqman
® 5’ allelic
discrimination assay. Prevalence of rs3212227 genotypes
in the parasitaemic children were 39.4% AA, 41.7% AC
and 18.9% CC with overall allele frequencies of A = 0.60
and C = 0.40, respectively. The combined distribution of
genotypes in the non-SMA and SMA groups displayed
significant departure from Hardy-Weinberg Equilibrium
(HWE, c
2 =9 . 0 7 8 ,P = 0.003). The distribution of
rs3212227 genotypes in the non-SMA group was 43.4%
AA, 40.5% AC, and 16.1% CC with allele frequencies of
A = 0.64 and C = 0.36, respectively (Table 2). The geno-
typic distribution in the non-SMA group had significant
departure from HWE (c
2 = 4.796, P = 0.030). Genotypic
distributions in SMA group were 34.2% AA, 43.3% AC,
and 22.5% CC with allele frequencies of A = 0.56 and C
= 0.44, respectively (Table 2). Departure from HWE did
not reach significance in children with SMA (c
2 = 3.536,
P =0 . 0 6 0 ) .T h eo v e r a l ld i s t ribution of genotypes
between the non-SMA and SMA groups was statistically
significant (c
2 test, P = 0.048, Table 2).
Cross-sectional association between rs3212227 genotypic
variants and SMA
To investigate the association between rs3212227 and
susceptibility to SMA in children with acute disease,
multivariate logistic regression analyses were performed
controlling for the confounding effects of age, gender,
sickle-cell trait, HIV-1, and bacteremia status [27-30].
Although heterozygous individuals (AC) had a 27% and
41% increased risk of developing SMA relative to homo-
zygous A individuals (wild type, reference) using Hb
cut-off criteria of 5.0 and 6.0 g/dL, respectively, these
results were not statistically significant (P = 0.314 and P
= 0.086, respectively; Table 3). However, homozygosity
at the C allele was associated with a 51% increased risk
of developing SMA using the WHO definition of disease
Table 1 Demographic, parasitological, and clinical
characteristics of the study participants upon enrolment
Characteristic Non-SMA SMA P
Participants, n 304 240 N/A
Gender, female, n (%) 140 (46.1) 122 (50.8) 0.268
a
Age, months 11 (10) 8 (7) <0.001
b
Axillary temperature, °C 37.5 (1.7) 37.4 (1.5) <0.001
b
Haemoglobin, g/dL 7.8 (2.7) 4.9 (1.4) <0.001
b
White blood cells, (×10
9/L) 10.9 (5.4) 13.1 (7.9) <0.001
b
Parasite density,/μL 19,932
(40,097)
17,262
(41,739)
0.446
b
Geomean parasitaemia,/μL 14,486 12,598 0.678
c
High-density parasitaemia, n
(%)
201 (66.1) 142 (59.2) 0.057
a
Sickle-cell trait, n (%) 49 (16.1) 6 (2.5) 0.054
a
Data are median values (interquartile range; IQR) unless otherwise noted.
Children with P. falciparum malaria (n = 544) were categorized according to
SMA status based on age- and geographically-appropriate Hb concentrations
[i.e., Hb<6.0 g/dL, with any density parasitaemia) [4]] and non-SMA (Hb≥6.0 g/
dL, with any density parasitaemia). High density parasitaemia (≥10,000
parasites/μL).
aStatistical significance determined by Chi-square analysis.
bStatistical significance determined by Mann-Whitney U test.
cStatistical
significance determined by independent groups t-test.
Table 2 Distribution of IL12B 3’ UTR genotypes in
children with P. falciparum malaria
IL12B 3’ UTR Genotypes Non-SMA SMA P
a
No. of participants, n 304 240
AA 132 (43.4) 82 (34.2)
AC 123 (40.5) 104 (43.3) 0.048
CC 49 (16.1) 54 (22.5)
P(A) = 0.64 P(A) = 0.56
Data are presented as proportion of individuals [n (%)] within non-SMA and
SMA groups. Children with P. falciparum malaria (n = 544) were categorized
according to SMA status based on age- and geographically-appropriate Hb
concentrations [i.e., Hb<6.0 g/dL, with any density parasitaemia) [4]] and non-
SMA (Hb≥6.0 g/dL, with any density parasitaemia).
aStatistical significance
determined by Chi-square analysis. The overall distribution of genotypes
between the non-SMA and SMA groups was statistically significant (c
2 test, P
= 0.048).
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0.142) and a 67% increased risk of SMA (Hb<6.0 g/dL,
OR, 1.674; 95% CI, 1.006-2.673; P = 0.047) using the
modified definition of SMA (Table 3). Additional ana-
lyses revealed that carriage of the C allele (AC + CC)
was associated with 35% increased risk of developing
SMA at Hb<5.0 g/dL (P = 0.170) and a 48% increased
risk of developing SMA at Hb<6.0 g/dL (P = 0.034,
Table 3). Although the CC vs. AC + AA demonstrated a
trend towards increased risk in those with CC genotype
relative to AC + AA groups, these findings were not sta-
tistically significant (Table 3). Further analyses stratify-
ing the genotypes into different alleles revealed the same
results for the A vs. C alleles and supported the obser-
vation that the presence of a C allele increased the risk
of developing SMA. Taken together, these results
demonstrate that carriage of the C allele is an important
risk factor for susceptibility to SMA in children with
acute disease using either the appropriately modified
definition of SMA or the more globally employed defini-
tion of SMA set by the WHO.
Functional relationship between rs3212227 genotypes
and IL-12 production
Prior to examining the functional association between
circulating IL-12 levels and rs3212227 variants, IL-12
levels were log-transformed towards normality and com-
pared between the non-SMA and SMA groups. Since
bacteremia and HIV-1 infection could influence cytokine
production in children with malaria, all co-infected chil-
dren were excluded from the analysis. Children with
SMA (n = 96) had significantly lower circulating IL-
12p40/p70 levels [mean (SEM); 2.563 (0.023)] than the
non-SMA (n = 98) group [2.638 (0.028), P = 0.037] (Fig-
ure 1a).
To determine if rs3212227 genotypes were associated
with functional changes in IL-12, circulating concentra-
tions of log-transformed IL-12p40/p70 levels were com-
pared across the genotypic groups. Levels of IL-12p40/
p70 were comparable in the groups (P =0 . 5 1 4 ,
ANOVA; Figure 1b), suggesting that variation at
rs3212227 may be an important marker of disease
severity, but may not be critical for regulating the over-
all production of IL-12 in children with acute malaria.
Longitudinal relationship between the rs3212227, SMA,
and mortality
After determining the relationship between the
rs3212227 locus and susceptibility to SMA in children
with acute malaria, hierarchical logistic regression was
used to investigate the relationship between carriage of
the different genotypes and longitudinal outcomes: SMA
and mortality. Genotypic distributions in the entire
cohort (n = 756) were: 40.3% (AA); 41.4% (AC); and
18.3% (CC). Hierarchical logistic regression modelling
revealed that relative to the AA genotype (reference),
neither the AC (b = -0.004, P = 0.963) nor CC (b =
0.005, P = 0.964) genotypes were associated with devel-
opment of SMA over the three year follow-up period.
The relationship between genotypes and mortality were
also examined by hierarchical logistic regression. The
m o r t a l i t yr a t eo v e rt h et h r e ey e a r so ff o l l o wu pw a s
7.1% (54/756). Compared to the AA reference group,
mortality over the follow-up period was not significantly
different for the AC (b = -0.571, P =0 . 1 3 0 )a n dC C( b
= -0.681, P = 0.181) genotypes. Further exploration by
both Poisson and Negative Binomial regressions also
failed to identify any significant relationships between
the genotypes and either susceptibility to SMA or mor-
tality (data not presented).
Discussion
The pathophysiological basis of SMA is complex and
poorly understood. One method for exploring the genes
and gene pathways that condition susceptibility to SMA
is to utilize a candidate gene approach for both cross-
sectional and longitudinal investigations. This approach
allows for an increased understanding of the mechan-
isms that confer protection against development of
SMA once children become infected with falciparum
malaria (acute disease), and also provides information
about how polymorphic variants condition susceptibility
to SMA and/or mortality throughout the critical phases
of naturally-acquired immunity (longitudinal outcomes).
Table 3 Relationship between IL12B3 ’ UTR genotypes and susceptibility to SMA
IL-12B 3’ UTR Genotype OR 95% CI P OR 95% CI P
SMA (Hb<5.0 g/dL) SMA (Hb<6.0 g/dL)
AA reference reference
AC 1.268 0.799-2.011 0.314 1.410 0.953-2.098 0.086
CC 1.512 0.870-2.629 0.142 1.674 1.006-2.673 0.047
CC vs. AC + AA 1.335 0.816-2.185 0.249 1.370 0.880-2.133 0.826
AA vs. AC+CC 1.346 0.881-2.058 0.170 1.479 1.031-2.123 0.034
Parasitaemic children (n = 544) were categorized according to the WHO SMA definition [i.e., Hb<5.0 g/dL, with any density parasitaemia [26]] and the age- and
geographically-appropriate definition of SMA [(Hb<6.0 g/dL, with any density parasitaemia [4]]. Odds Ratio (OR) and 95% confidence interval (CI) were
determined using multivariate logistic regression controlling for age, gender, HIV-1, bacteremia, and sickle-cell trait (HbAS) status.
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provide important information about the role of IL-12
in protecting against SMA.
Children with falciparum malaria underwent extensive
clinical evaluations to rule out additional causes of anae-
mia so that they could be appropriately controlled for in
the multivariate models. For example, since HIV-1 and
bacteremia are some of the most common anaemia-pro-
moting infectious diseases in African children [27-29],
all study participants were tested for these co-pathogens.
It is important to note that children exposed to HIV-1,
yet lack definitively identifiable virus in their system,
also have enhanced severity of anaemia when they
acquire falciparum malaria [27]. Unlike previous studies,
the multivariate models therefore controlled for HIV-1
exposure, HIV-1 positivity, and bacteremia. Since severe
anaemia is the primary manifestation of severe malaria
in holoendemic P. falciparum transmission regions, with
cerebral malaria being a rare occurrence, this study spe-
cifically examined the role of rs3212227 in conditioning
the development of severe anaemia and as such, it
remains to be determined if results obtained here are
applicable to areas with differing endemicities of malaria
in which individuals develop severe disease manifesta-
tions apart from severe anaemia.
IL-12 plays a critical role in modulating the immune
response by promoting CD4+ T cells and NK cells to
differentiate towards a Th1 phenotype for production of
IFN-g, an important component of cell-mediated immu-
nity that helps eliminate intracellular pathogens [31].
Accumulating evidence shows that IL-12 is a critical fac-
tor for augmenting protective immune responses against
malaria in animal models [7,32,33]. Our previous studies
showing that reduced IL-12p70 production is associated
with enhanced severity of malaria in African children
[8,34] illustrate the importance of IL-12 in human
malaria as well. Consistent with these investigations, the
current study demonstrated that children with acute
malaria that develop SMA have significantly lower circu-
lating IL-12p40/p70 levels than children that fail to pro-
gress to severe anaemia (i.e., the non-SMA group).
Previous examination of the rs3212227 polymorphism
in Tanzanian children demonstrated that homozygous C
individuals had higher mortality from cerebral malaria,
whereas no significant associations were found between
rs3212227 genotypes and severe malaria (defined as a
mixed phenotypic outcome) in children from coastal
Kenya [14]. Our recent study in Thai adults with falci-
parum malaria showed that although carriage of the
rs3212227 CC genotype was enriched in the severe dis-
ease group, multivariate modelling did not reveal a sig-
nificant association between the genotype and disease
severity [23]. In addition, a comprehensive longitudinal
study in an adjacent region to where the current study
was conducted utilized fifty-five tagging single nucleo-
tide polymorphisms (covering genes encoding IL12A,
IL12B, IL12RB1, and IL12RB2) to demonstrate a number
of important associations between genetic variation and
SMA, of which rs3212227 did not emerge as significant
[24]. However, results presented here clearly demon-
strate that homozygosity at the C allele was associated
with an increased risk of developing SMA in children
with acute disease, while having no effect on longitudi-
nal outcomes (i.e., SMA and mortality) over three years
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Figure 1 IL-12p70 production based on anaemia severity and
genotypes. (A) The association between circulating IL-12p40/p70
levels and anaemia severity in parasitaemic children with SMA (n =
95) and non-SMA (n = 95) was determined. Bar-charts represent the
means, and whiskers show the standard error of mean (SEM).
Statistical significance was determined at P ≤ 0.05 by independent
groups t-test. Children with SMA had significantly lower circulating
IL-12p40/p70 levels than the non-SMA group (P = 0.037). (B)
Circulating IL-12p40/p70 levels in children (n = 190) with P.
falciparum malaria were measured using the Human Cytokine 25-Plex
Antibody Bead Kit and stratified according to genotype. Bar-charts
represent the means, and the whiskers show the standard error of
mean (SEM) for AA (n = 69) 2.625 ± 0.035, AC (n = 82) 2.576 ± 0.027,
and CC (n = 39) 2.590 ± 0.030 genotypes. Differences were
considered significant at P ≤ 0.05 (ANOVA). IL-12p40/p70 levels were
not significantly different across the genotypic groups (P = 0.514).
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predominately Luo ethnic populations examined in both
studies is unclear, it may be attributable to the fact that
we controlled for the influence of common paediatric
infectious diseases, such as HIV-1 and bacteremia, that
influence both anaemia and mortality throughout child-
hood. Furthermore, the distribution of genotypes in the
combined clinical groups (non-SMA and SMA) dis-
played significant departure from HWE, possibly result-
ing from selection at the rs3212227 SNP due to
‘enrichment’ of malaria-infected individuals in the cur-
rent study. Although not available for the current study,
examination of the genotypes in a large number of non-
malaria infected ‘controls’ w o u l dh e l pt od e t e r m i n ei f
the HWE deviation at rs3212227 observed in the current
study is indeed due to malaria-mediated selection.
Since 3’UTRs contain regulatory elements that are
highly conserved and control translational activity, varia-
tion within the 3’UTR can affect transcriptional stability
and binding of translational proteins [35]. A previous
investigation examining the rs3212227 in Turkish adults
showed that individuals with the CC genotype produced
the highest levels of IL-12p70 in cultured peripheral
blood mononuclear cells (PBMC) [22,36], while another
study in two ethnic groups from Bulgaria revealed that
the AA genotype was associated with the highest PBMC
IL-12p40 production [22,36]. However, recent studies in
individuals with lepromatous leprosy and Chagas’ disease
failed to find any significant relationships between
rs3212227 genotypes and IL-12p70 production [20,21].
Consistent with these investigations, stratification of chil-
dren in the current study, according to genotypes, failed
to show any significant differences in circulating IL-
12p40/p70 levels across the groups. Moreover, examina-
tion of IL-12p40/70 in cultured PBMC from children
with malaria in the current study also failed to show any
significant association with rs3212227 genotypes (data
not presented). The lack of a functional association
between rs3212227 variants and IL-12 production
reported here is supported by our in silico analysis (using
the web site http://www.cbil.upenn.edu/cgi-bin/tess/tess)
which revealed that the region encompassing the
rs3212227 had no major transcription factor binding site
changes that would be affected by SNP variation within
this region. Although the exact reason for the lack of a
functional association between rs3212227 genotypes and
IL-12p40/p70 levels reported here remains to be deter-
mined, it is possible that additional polymorphic variants,
such as IL12Bpro [14], or variation in other genes that
influence IL-12 production (e.g. IL-10 and IL-4) may be
responsible for mediating IL-12 generation [36,37].
Since the mechanism through which IL-12 provides pro-
tection against malaria in murine models appears to be
related to the ability of IL-12 to promote IFN-g and tumour
necrosis factor (TNF)-a production that, in turn, provide
enhanced NO generation [38], we examined the association
between the rs3212227 variants and all three of these
inflammatory mediators. However, circulating levels of
IFN-g,T N F - a, or NO were not significantly different upon
stratifying into genotypic groups (data not presented).
Recent data from our laboratory, obtained in the same
population of children, demonstrated that multi-site loci
provide more informative information about malarial dis-
ease outcomes than information obtained for a single locus
[39,40]. These studies further revealed that combinations of
functional polymorphic alleles in haplotypes interact to
modulate the individual effects of SNPs and variable num-
ber tandem repeats (VNTRs) [39,41]. As such, we are cur-
rently expanding the current study to include additional
polymorphisms in the IL12B gene (and other immunoregu-
latory genes that influence IL-12), to delineate the effects of
genetic variation in cis-regulatory genes, and the impact of
haplotypes on the host immune response to malaria.
Conclusions
Results presented here demonstrate that the rs3212227 is
an important marker of susceptibility to SMA, but varia-
tion at this particular locus may not serve as a functional
mediator of IL-12p40/p70 levels. Given that similar results
were observed in individuals with lepromatous leprosy
[20] and Chagas’ disease [21], the CC genotype could be a
marker of susceptibility to intracellular pathogens. Addi-
tional studies are required to confirm this hypothesis.
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